Drug Type Proteolysis-targeting chimeras |
Synonyms |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization AevisBio, Inc.Startup |
Active Organization AevisBio, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hematologic Neoplasms | Phase 1 | KR | AevisBio, Inc.Startup | 30 May 2023 |
Breast Cancer | Preclinical | KR | AevisBio, Inc.Startup | 20 Jul 2023 |
Lung Cancer | Preclinical | KR | AevisBio, Inc.Startup | 20 Jul 2023 |
Multiple Myeloma | Preclinical | KR | AevisBio, Inc.Startup | 20 Jul 2023 |